Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 11:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: QBW251 Clear all
Completed Phase 2 Interventional Results available

Dose-range Finding Efficacy and Safety Study for QBW251 in COPD Patients

NCT04072887
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
QBW251, Placebo, COPD maintenance background therapy
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
974 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Andalusia, Alabama • Los Angeles, California • Westminster, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2023 · Synced Oct 17, 2026, 11:31 AM EDT
Completed Phase 2 Interventional Results available

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251

NCT02449018
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease, COPD
Interventions
QBW251, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
14
States / cities
Birmingham, Alabama • Fullerton, California • Waterbury, Connecticut + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 17, 2026, 11:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Icenticaftor in Participants With Hepatic Impairment

NCT04587622
View directory record Official record
Conditions
Hepatic Failure
Interventions
Icenticaftor
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Miami, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 17, 2026, 11:31 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

NCT02190604
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo, QBW251
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
9
States / cities
Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 17, 2026, 11:31 AM EDT